• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    PRESIDENT & CFO Horn David R. sold $14,028 worth of shares (6,760 units at $2.08), decreasing direct ownership by 2% to 443,629 units (SEC Form 4)

    5/22/25 4:13:53 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Horn David R.

    (Last) (First) (Middle)
    C/O SEER, INC.
    3800 BRIDGE PARKWAY, SUITE 102

    (Street)
    REDWOOD CITY CA 94065

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Seer, Inc. [ SEER ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    PRESIDENT & CFO
    3. Date of Earliest Transaction (Month/Day/Year)
    05/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 05/20/2025 S(1) 6,760 D $2.0751 443,629 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.
    /s/ David R. Horn 05/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SEER alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Seer Inc.

      SC 13G/A - Seer, Inc. (0001726445) (Subject)

      8/2/24 6:33:25 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Seer Inc.

      SC 13G/A - Seer, Inc. (0001726445) (Subject)

      7/8/24 4:32:39 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Seer Inc. (Amendment)

      SC 13G/A - Seer, Inc. (0001726445) (Subject)

      4/10/24 10:06:09 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Seer with a new price target

      JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

      7/5/23 7:25:16 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer downgraded by BofA Securities with a new price target

      BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

      1/4/23 9:03:59 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer downgraded by JP Morgan with a new price target

      JP Morgan downgraded Seer from Overweight to Neutral and set a new price target of $12.00 from $20.00 previously

      8/11/22 6:17:02 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    See more
    • Seer Appoints Nicolas Roelofs to its Board of Directors

      REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

      8/14/24 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

      REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented

      3/16/22 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Appoints Meeta Gulyani to its Board of Directors

      REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Executive Vice President, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, a global science and technology company, which operates as MilliporeSigma in the U.S. and Canada. "Meeta is a seasoned life sciences and pharma leader with global experience across markets, including Asia, an important market for Seer, and we are really pleased to welcome Me

      11/29/21 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Financials

    Live finance-specific insights

    See more
    • Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

      REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with Discovery Life SciencesAccelerated third-party validation of platform through increasing number of customer publications, webinars, preprints and reviewsEnded the quarter with approximately $285 million of cash, cash equivalents and investments "We are proud of our

      5/13/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer to Report First Quarter 2025 Financial Results on May 13, 2025

      REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to the

      4/24/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook

      REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Achieved revenue of $4.0 million for the fourth quarter of 2024 and $14.2 million for the full year 2024Shipped 10 instruments during 2024, bringing cumulative instruments shipped to 72 as of December 31, 2024Launched a new product application for the Proteograph XT workflow, specifically designed for cell lysis proteomics, unlocking unprecedented depth in intracellular proteomicsShowcased new findings and a

      2/27/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

      REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics. Seer's newest innovation, debuting at the upcoming American Society for Mass Spectrometry (ASMS) annual conference in Baltimore, MD, overcomes the challenges of large-scale proteomic studies that had been hindered by limited throughput and prohibitive costs. It significantly enhances the flagship Proteograph Product Suit

      5/29/25 7:00:00 AM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

      REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with Discovery Life SciencesAccelerated third-party validation of platform through increasing number of customer publications, webinars, preprints and reviewsEnded the quarter with approximately $285 million of cash, cash equivalents and investments "We are proud of our

      5/13/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Seer to Report First Quarter 2025 Financial Results on May 13, 2025

      REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to the

      4/24/25 4:05:00 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Seer Inc.

      DEFA14A - Seer, Inc. (0001726445) (Filer)

      5/28/25 4:21:27 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Seer Inc.

      DEF 14A - Seer, Inc. (0001726445) (Filer)

      5/28/25 4:19:40 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Seer Inc.

      SCHEDULE 13G/A - Seer, Inc. (0001726445) (Subject)

      5/14/25 4:01:18 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CFO Horn David R. sold $14,028 worth of shares (6,760 units at $2.08), decreasing direct ownership by 2% to 443,629 units (SEC Form 4)

      4 - Seer, Inc. (0001726445) (Issuer)

      5/22/25 4:13:53 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CEO AND CHAIR Farokhzad Omid sold $69,854 worth of shares (33,663 units at $2.08), decreasing direct ownership by 3% to 1,306,060 units (SEC Form 4)

      4 - Seer, Inc. (0001726445) (Issuer)

      5/22/25 4:10:49 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CFO Horn David R. covered exercise/tax liability with 26,572 shares, decreasing direct ownership by 6% to 450,389 units (SEC Form 4)

      4 - Seer, Inc. (0001726445) (Issuer)

      2/20/25 4:13:50 PM ET
      $SEER
      Biotechnology: Laboratory Analytical Instruments
      Industrials